Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 48 results for uterine fibroids

  1. Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroids: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 16 June 2026.

    In consultation

  2. Laparoscopic laser myomectomy (HTG9)

    Evidence-based recommendations on laparoscopic laser myomectomy. This involves passing a fine telescope (laparascope) through small cuts in the abdomen and uterus wall, and using a laser to destroy the fibroids.

    HealthTech guidance
    Published
    26 November 2003
    View recommendations

    Sections for HTG9

  3. Heavy menstrual bleeding (QS47)

    This quality standard covers assessing and managing heavy menstrual bleeding (menorrhagia), including suspected or confirmed fibroids and adenomyosis. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    16 October 2020
    View quality statements

    Sections for QS47

  4. Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)

    This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77

    Network / system level indicators
    Last updated
    22 March 2024

  5. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-HTG10171 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  6. Laparoscopic techniques for hysterectomy (HTG153)

    Evidence-based recommendations on laparoscopic techniques for hysterectomy. This involves surgically removing the uterus using special instruments through small cuts in the abdomen (keyhole surgery).

    HealthTech guidance
    Published
    28 November 2007
    View recommendations

    Sections for HTG153

  7. Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on efficacy is limited in quality. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    ultrasound-guided high‑intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised...

    Research recommendation
    Published
    15 November 2019

  8. Second-generation endometrial ablation for HMB associated with myometrial pathology:- Are outcomes after second-generation endometrial ablation for women with HMB associated with myometrial pathology (adenomyosis and/or uterine fibroids) equivalent to those for women without myometrial pathology?

    women with HMB associated with myometrial pathology (adenomyosis and/or uterine fibroids) equivalent to those for women without...

    Research recommendation
    Published
    14 November 2018

  9. NICE encourages further research into the efficacy of MRI-guided transcutaneous focused ultrasound for uterine fibroids. Research studies should report long-term outcomes, including the need for further treatment. Data on the incidence and outcomes of subsequent pregnancy in patients who choose this procedure because they wish to maintain or improve their fertility are particularly important.

    into the efficacy of MRI-guided transcutaneous focused ultrasound for uterine fibroids. Research studies should report long-term...

    Research recommendation
    Published
    9 June 2015

  10. Evidence on the safety of laparoscopic removal of uterine fibroids with power morcellation shows potentially serious complications. In particular there is a risk of spreading undiagnosed malignant tissue, which has higher prevalence in people who are postmenopausal or over 50. Evidence on the procedure's efficacy is limited in quantity. Therefore, further research should report details of patient selection, surgical technique (including any containment system used) and long-term outcomes.

    Question Evidence on the safety of laparoscopic removal of uterine fibroids with power morcellation shows potentially serious...

    Research recommendation
    Published
    30 September 2021

  11. Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

    Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding in adults.

    Technology appraisal guidance
    Published
    28 April 2004
    View recommendations

    Sections for TA78

  12. Uterine artery embolisation for treating adenomyosis (HTG324)

    Evidence-based recommendations on uterine artery embolisation for treating adenomyosis. This involves injecting small particles to block the blood supply to the adenomyosis (thickening of the womb lining).

    HealthTech guidance
    Published
    16 December 2013
    View recommendations

    Sections for HTG324

  13. Hysteroscopic removal of submucosal fibroids compared with other uterine-sparing treatments for HMB:- Is hysteroscopic removal of submucosal fibroids more effective and cost-effective than other uterine-sparing treatments for the management of HMB?

    removal of submucosal fibroids compared with other uterine-sparing treatments for HMB:- Is hysteroscopic removal of...

    Research recommendation
    Published
    14 November 2018

  14. Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions (HTG699)

    Evidence-based recommendations on vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. This involves removing the uterus (womb), and sometimes the fallopian tubes and ovaries, through the vagina.

    HealthTech guidance
    Published
    25 October 2023
    View recommendations

    Sections for HTG699

  15. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1057